Navigation Links
Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action

SALT LAKE CITY, June 14, 2007 /PRNewswire/ -- Prolexys Pharmaceuticals and announced today a publication describing the properties of the selective small molecule anti-tumor agent, erastin. Prolexys and Columbia applied the company's chemi-proteomics technology to understand the mechanism of action of erastin. The results, to be published in the June 14, 2007 issue of the journal Nature reveal that erastin binds to mitochondrial voltage- dependent anion channels (VDACs) -- a novel target for anti-cancer drugs. Knock-down of VDAC2 and VDAC3 gene expression causes resistance to erastin, implicating the involvement of these two proteins in erastin-mediated cell death. Treatment of cells with erastin results in VDAC-protein-mediated mitochondrial dysfunction, release of oxidative species and, ultimately, cell death. This process has a degree of selectivity for cells with aberrantly active RAS pathway. In normal cells, RAS pathway is involved in growth and differentiation of cells; however the aberrant activation of this pathway results in uncontrolled tumor growth.

Dr. Brent Stockwell, currently an Associate Professor of Biological Sciences and of Chemistry at , identified erastin as a small molecule anti-cancer agent that exhibits lethality in human tumor cells with mutations in RAS-related cancer genes such as HRAS, KRAS or BRAF, beginning when he was a Fellow at the Whitehead Institute for Biomedical Research. In February 2005, Prolexys signed an exclusive licensing agreement with the Massachusetts Institute of Technology, as the licensing agent of , and the Whitehead Institute, which provides Prolexys with exclusive, worldwide rights to a patent estate covering selective anti-tumor compounds in the erastin family. "This paper demonstrates that it is feasible to discover compounds that produce cancer-cell-selective toxicity and to use these to understand cell death mechanisms in cancer cells; furthermore, the approach revealed a novel cell death pathway," said Dr. Stockwell.

Prolexys launched a medicinal chemistry effort in 2005 to create small molecule analogs of erastin with improved pharmaceutical properties. This effort resulted in the identification of a close structural analog, PRLX 93936, which shows improvement in potency, solubility, and in vivo activity, compared to erastin. PRLX 93936 shows robust and selective toxicity in a wide variety of tumor cell-lines, and causes complete tumor regression in mouse xenograft models of fibrosarcoma, pancreatic cancer, ovarian cancer, colon cancer, and melanoma. Prolexys plans to file an Investigational New Drug (IND) Application for PRLX 93936 with the U.S. Food and Drug Administration (FDA) in June, 2007. Although PRLX 93936 was created as a result of screening hundreds of erastin-related small molecules, its molecular mechanism of action may differ from those of erastin. "Prolexys and collaborators continue to work towards understanding the molecular basis of the unique tumor-selective mechanism of action of erastin and PRLX 93936," said Dr. Sudhir Sahasrabudhe, Chief Scientific Officer of Prolexys Pharmaceuticals.

"The approach described in this paper is a powerful way to identify and test small molecule therapeutics and translate them into the clinic in a time- efficient and cost-efficient manner. We are very excited about evaluating the therapeutic potential of molecules with novel mechanisms of action, such as PRLX 93936 in patients with pancreatic cancer and other solid tumors," said Dr. Daniel Von Hoff, Principal clinical investigator of PRLX 93936, and TGen's Physician-in-Chief and Director of TGen's Clinical Research Service in Scottsdale, Arizona

About Prolexys Pharmaceuticals: Prolexys Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on discovering small molecule drugs that act on novel therapeutic targets. The Company's therapeutic focus is in cancer and res piratory disease indications where Prolexys has identified novel therapeutic targets and small molecule compounds active at these targets. Prolexys' ability to identify and validate novel targets is driven by its technological leadership in the field of proteomics and the application of proteomics technologies to its own, and its partners, drug discovery programs. For more information about Prolexys, visit the company's website at

About Columbia University: A leading academic and research university, Columbia continually seeks to advance the frontiers of knowledge and to foster a campus community deeply engaged in understanding and addressing the complex global issues of our time. Columbia's extensive public service initiatives, cultural collaborations and community partnerships help define the University's underlying values and mission to educate students to be both leading scholars and informed, engaged citizens. Founded in 1754 as King's College, in the City of New York is the country's fifth oldest institution of higher learning.

CONTACT: Dr. Sudhir Sahasrabudhe, CSO of Prolexys Pharmaceuticals,+1-801-303-1714

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical ...  - 22 nd April 2016. --> --> ... --> -->   --> ... aging population and the government back up, the Medical Device is one of ... States . With the aging population and the government back up, the ...
(Date:11/30/2015)... 30, 2015 Nevro Corp. (NYSE: NVRO ), ... solutions for the treatment of chronic pain, today announced that ... Patent and Trademark Office (USPTO) has denied instituting an ... (the ,102 patent).  --> ... Scientific Corporation filed two petitions challenging the validity of certain ...
(Date:11/30/2015)... , Nov. 30, 2015 ... of the "Orphan Drugs Market 2015-2019" ... ) has announced the addition of the ... offering. --> Research and Markets ( ... "Orphan Drugs Market 2015-2019" report to ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum of Science & ... a new era of publicly accessible automated technology. Now, by popular demand, the ... guests an up-close look at the shuttle at MOSI’s main entrance. This experience ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals ... So why is it a national news story when Donald Trump makes disparaging remarks ... because appearances count more than anyone wants to admit when it comes to how ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... course in Dallas, TX, on January 29 and 30, 2016. The course welcomes ... functions of their practices, to learn how to better succeed in the modern ...
(Date:11/30/2015)... Georgia (PRWEB) , ... November 30, 2015 , ... ... of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant ... at Georgia State University. , Their study showed that small molecule analogs that ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies specializes in orthodontics ... visit Dr. Margulies to experience the best available orthodontic experience in the area. ... Top Dentist"! , Orthodontics is the branch of dentistry that specializes in the diagnosis, ...
Breaking Medicine News(10 mins):